The clinical information you need, at your fingertips.

In more than 3,400 US patients with metastatic hormone-sensitive prostate cancer, apalutamide or enzalutamide was linked to a 26% lower risk of death. . .

Patients using telehealth were more likely to obtain care earlier in pregnancy and live farther from abortion facilities than those traveling for in-clinic services. . .

Pooled phase 3 data suggest mepolizumab may reduce reliance on systemic corticosteroids, especially high-dose courses. . .

The potential first-in-class individualized neoantigen therapy yielded positive results that were publicly tipped ahead of the European Society for Medical Oncology presentation tomorrow. . .